Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Sell BPCL; buy SBI, Axis Bank on dips: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends selling BPCL and advises buying State Bank of India and Axis Bank on dips.

    • Buy HUL, Dabur, Sun Pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Hindustan Unilever, Dabur India and Sun Pharma.

    • Buy pharma stocks, says Dhananjay Sinha

      Dhananjay Sinha of Emkay Global Fin Services is of the viwe that one can buy pharma stocks.

    • Short HDFC, TVS Motor, Tata Steel: Aditya Agarwal

      Aditya Agarwal of Way2Wealth Securities is of the view that one can short HDFC, TVS Motor and Tata Steel.

    • Buy Century Textiles, Sun Pharma: Kunal Bothra

      Kunal Bothra, Head of Advisory at LKP Securities is of the view that one may buy Century Textiles and Sun Pharma.

    • Prefer Alembic Pharma: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that one may prefer Alembic Pharmaceuticals from the pharma space.

    • Prefer pharma, Alembic Pharma looks interesting: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that there are opportunities in pharma stocks and feels that Alembic Pharma looks interesting.

    • Stay invested in Sun Pharma, says Ashish Kyal

      Ashish Kyal of wavesstrategy.com is of the view that one may stay invested in Sun Pharma.

    • Positive on largecap pharma stocks, cement: Deven Choksey

      Deven Choksey of KRChoksey Investment Managers has a positive view on largecap pharma stocks and the cement space.

    • Buy Infosys, Sun Pharma; sell Just Dial: Ashish Kyal

      Ashish Kyal of wavesstrategy.com is of the view that one can buy Infosys and Sun Pharma and advises selling Just Dial.

    • Sun Pharma may test Rs 885-900, says Yogesh Mehta

      Yogesh Mehta of Motilal Oswal Securities is of the view that Sun Pharma may test Rs 885-900.

    • Sell JSW Steel, Sun Pharma may hit Rs 860: Rajat Bose

      Rajat Bose of rajatkbose.com recommends selling JSW Steel and feels that Sun Pharma may hit Rs 860.

    • Add Maruti Suzuki to portfolio: Deven Choksey

      Deven Choksey of KR Choksey Investment Managers is of the view that one can add Maruti Suzuki to the portfolio.

    • Buy Sun Pharma 840 Call, Dr Reddy's Labs 3100 Call: VK Sharma

      VK Sharma of HDFC Securities is of the view that one can buy Sun Pharma 840 Call and Dr Reddy's Labs 3100 Call.

    • Cautious on pharma space, says Mahantesh Sabarad

      Mahantesh Sabarad, Deputy VP-Research, SBICap Securities has a cautious view on the pharma space.

    • Buy Sun Pharma, sell SBI: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Sun Pharma and advises selling State Bank of India.

    • Buy Sun Pharmaceutical, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Sun Pharmaceutical Industries.

    • Buy Sun Pharma, Infosys, JSW Steel: Rakesh Bansal

      Rakesh Bansal of RK Global recommends buying Sun Pharma, Infosys and JSW Steel.

    • Sell PNB, SBI; buy Sun Pharma, Reliance Industries: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can sell Punjab National Bank and State Bank of India and advises buying Sun Pharma and Reliance Industries.

    • Buy Hero Moto, Sun Pharma on dips; avoid L&T: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Hero Motocorp and Sun Pharma on dips and feels that one can avoid Larsen & Toubro.

    • Super Six: Top chart picks for January 20

      Gaurav Ratnaparkhi of Sharekhan advises buying Ashok Leyland with a target of Rs 92.

    • Buy Glenmark Pharma; like Lupin, Dr Reddy's Lab: Abhishek Sharma

      Abhishek Sharma, Pharma Analyst at IIFL recommends buying Glenmark Pharma and likes Lupin and Dr Reddy's Labs.

    • Buy Sun Pharma; sell Tata Motors, IFCI: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Sun Pharma and Apollo Hospitals and advises selling Tata Motors and IFCI.

    • Pharma, consumer discretionary look attractive: Nilesh Shah

      Nilesh Shah - MD & CEO at Envision Capital is of the view that pharma, consumer discretionary and cement sectors look attractive with a view of 2-3 years.

    • Godrej Cons defensive buy, HCL tech may move up: Prakash Gaba

      Prakash Gaba, Technical Analyst at prakashgaba.com is of the view that Godrej Consumer is a defensive buy and feels that HCL Tech may move higher.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347